SCHEMBL7899484

SCHEMBL7899484

COC(=O)/C=C/c1ccc(CNC(C)(C)C(=O)OC2CCCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 15/20 0.44
HDAC8 Q9BY41 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
KDM1A O60341 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
TYR P14679 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9894329 1.00 NR1H4 (0.44) NR1H4HDAC8HDAC6KDM1ACA12
SCHEMBL9896126 0.89 HDAC3 (0.55) HDAC8HDAC6KDM1AHDAC3HDAC4
SCHEMBL7899146 0.89 HDAC3 (0.55) HDAC8HDAC6KDM1AHDAC3HDAC4
Trifluoroacetic Acid SCHEMBL9895594 0.83 HDAC3 (0.49) HDAC8HDAC6KDM1AHDAC3HDAC4
SCHEMBL1199017 0.80 CACNA1B (0.47) HDAC3HDAC1HTTRAB9A
SCHEMBL7897999 0.79 HDAC3 (0.51) HDAC8HDAC6KDM1AHDAC3HDAC4
SCHEMBL9894398 0.79 HDAC3 (0.51) HDAC8HDAC6KDM1AHDAC3HDAC4
SCHEMBL9894399 0.79 HDAC3 (0.51) HDAC8HDAC6KDM1AHDAC3HDAC4
SCHEMBL9896193 0.78 HDAC3 (0.52) HDAC8HDAC6KDM1AHDAC3HDAC4
SCHEMBL7900767 0.78 HDAC3 (0.52) HDAC8HDAC6KDM1AHDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140155439-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2014-06-05 US disclosed
US-20140155439-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2014-06-05 US disclosed
US-20130303576-A1 ENZYME INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2013-11-14 US disclosed
US-20130303576-A1 ENZYME INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2013-11-14 US disclosed
US-20120149736-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2012-06-14 US disclosed
US-20120149736-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2012-06-14 US disclosed
WO-2010097586-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303576-A1 ENZYME INHIBITORS HDAC1, HDAC4, HDAC3 NR1H4 119/4885HDAC8 13/4885HDAC6 45/4885
US-20140155439-A1 ENZYME INHIBITORS HDAC4, HDAC1, HDAC3 NR1H4 300/4885HDAC8 11/4885HDAC6 77/4885
US-20120149736-A1 ENZYME INHIBITORS HAT1, HDAC1, NAT1 NR1H4 130/4885HDAC8 10/4885HDAC6 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.